While the commercial potential of the Anti-Cathepsin B Market is undeniably massive, the industry must navigate a complex matrix of technical challenges and stringent regulatory frameworks to achieve widespread commercial scaling. One of the primary scientific hurdles lies in the inherent structural similarity between Cathepsin B and other members of the lysosomal cysteine protease family, such...